IINX yields 200000000.00% · ABBV yields 3.12%● Live data
📍 IINX pulled ahead of the other in Year 1
Combined, IINX + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IINX + ABBV for your $10,000?
Ionix Technology, Inc., together with its subsidiaries, engages in the research and development, manufacture, and marketing of liquid crystal materials, displays, and modules in the United States, Hong Kong, and the People's Republic of China. It operates through three segments: Smart Energy, Photoelectric Display, and Service Contracts. The company provides electronic equipment, such as power banks for iphone, ipad, mp3/mp4 players, PSP gaming systems, and cameras; and liquid crystal module and liquid crystal display screens for video capable baby monitors, tablets and cell phones, and televisions or computer monitors. It distributes its products to distributors and retailers. The company was formerly known as Cambridge Projects Inc. and changed its name to Ionix Technology, Inc. in February 2016. Ionix Technology, Inc. was incorporated in 2011 and is based in Dalian, China. Ionix Technology, Inc. is a subsidiary of Shining Glory Investments Limited.
Full IINX Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.